Akums Drugs & Pharmaceuticals Ltd (AKUMS) Stock Analysis: Valuation, Latest Results, Financial Ratios & DeciZen Rating

BSE: 544222 | NSE: AKUMS | Pharmaceuticals & Drugs | Small Cap

Akums Drugs & Pharma Share Price

419.85 -0.45 -0.11%
as on 05-Dec'25 15:23

Akums Drugs & Pharmaceuticals Ltd (AKUMS) Stock Analysis: Valuation, Latest Results, Financial Ratios & DeciZen Rating

BSE: 544222 | NSE: AKUMS | Pharmaceuticals & Drugs | Small Cap

DeciZen - make an informed investing decision on Akums Drugs & Pharma

Based on:

Overall Rating
Login to view analysis. Bole Toh

1. Quality


Login to view analysis.

2. Valuation


Login to view analysis.

3. Price Trend


Login to view analysis.

Akums Drugs & Pharmaceuticals stock performance -

Key Ratios
mw4me loader
P/E Ratio (SA):
48.26
Market Cap:
6,615.3 Cr.
52-wk low:
407.4
52-wk high:
678.8

Is Akums Drugs & Pharmaceuticals Ltd an attractive stock to invest in?


Login to view analysis.

10 Year X-Ray of Akums Drugs & Pharma: Login to view analysis.

Analysis of Financial Track Record

Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end
Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end

Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end.

Financial track record gives insight into the company's performance on key parameters over the past ten years. MoneyWorks4me’s proprietary colour codes make it easy for retail investors to gauge the company’s past performance.
Akums Drugs & Pharmaceuticals Ltd has performed well in some of the past ten years indicating its past ten year financial track record is somewhat good

Value Creation

Value Creation Index Colour Code Guide

Mar'16Mar'17Mar'18Mar'19Mar'20Mar'21Mar'22Mar'23Mar'24Mar'25TTM
ROCE % 8.5%6.6%13.8%13.7%9.8%-29.1%-73.8%42.8%-20.5%16.7%-
Value Creation
Index
-0.4-0.50.00.0-0.3-3.2-6.52.2-2.50.2-

Growth Parameters

Growth Parameters Colour Code Guide

Sales 5646285966837378371,1621,2871,4441,3121,308
Sales YoY Gr.-11.3%-5.2%14.7%7.9%13.6%38.8%10.7%12.2%-9.2%-
Adj EPS 3.62.55.25.73.62-27.115.46.410.18.7
YoY Gr.--30.3%111.3%9%-37.8%-42.5%-1427%NA-58.2%57.7%-
BVPS (₹) 51.554.159.465.149.839.61321.810.1150.6150.8
Adj Net
Profit
46.132.167.773.950.829.2-38722092.1155137
Cash Flow from Ops. 3.444.171.42.8-21.855.62289424891-
Debt/CF from Ops. 181.30.518.2-1.70.40.51.60.90-

CAGR

CAGR Colour Code Guide

9 Years 5 Years 3 Years 1 Years
Sales 9.8%12.2%4.1%-9.2%
Adj EPS 12.3%23.4%NA57.7%
BVPS12.7%24.8%126.4%1396.7%
Share Price - - - -31.1%

Key Financial Parameters

Performance Ratio Colour Code Guide

Mar'16Mar'17Mar'18Mar'19Mar'20Mar'21Mar'22Mar'23Mar'24Mar'25TTM
Return on
Equity %
7.24.79.29.26.54.6-102.988.540.412.75.8
Op. Profit
Mgn %
7.64.712.6125.43.2-31.215.41610.38.6
Net Profit
Mgn %
8.25.111.410.86.93.5-33.317.16.411.810.5
Debt to
Equity
0.10.100.10.100.70.51.600
Working Cap
Days
386346406407458417355404381432155
Cash Conv.
Cycle
1171029288938262605452114

Recent Performance Summary

Login to view analysis.
Login to view analysis.

Latest Financials - Akums Drugs & Pharmaceuticals Ltd.

Standalone Consolidated
TTM EPS (₹) 8.7 20.1
TTM Sales (₹ Cr.) 1,308 4,108
BVPS (₹.) 150.8 200.1
Reserves (₹ Cr.) 2,342 3,118
P/BV 2.79 2.10
PE 48.26 20.86
From the Market
52 Week Low / High (₹) 407.40 / 678.80
All Time Low / High (₹) 407.40 / 1174.85
Market Cap (₹ Cr.) 6,615
Equity (₹ Cr.) 31.5
Face Value (₹) 2
Industry PE 40.7

Management X-Ray of Akums Drugs & Pharma:

Shareholding Pattern

Promoter's Holding & Share Pledging

Pledged *0.000.000.000.000.00
* Pledged shares as % of Promoter's holding (%)

Valuation of Akums Drugs & Pharma - Standalone Basis

YTD 1Y 3Y 5Y 10Y Max
mw4me loader

YTD 1Y 3Y 5Y 10Y Max
mw4me loader

YTD 1Y 3Y 5Y 10Y Max
mw4me loader

YTD 1Y 3Y 5Y 10Y Max
mw4me loader

mw4me loader

Event Update

Login/Register to view analysis.

Analyst's Notes

data not found
No data found!

Key Ratios of Akums Drugs & Pharma

Adj EPS (Rs.)

Sales (Cr.)

ROE (%)

ROCE (%)

Profit And Loss

(All Figures are in Crores.)
PARTICULARSMar'16Mar'17Mar'18Mar'19Mar'20Mar'21Mar'22Mar'23Mar'24Mar'25
Sales5646285966837378371,1621,2871,4441,312
Operating Expenses 5225995216016978111,5241,0891,5711,177
Manufacturing Costs4247394458517295105114
Material Costs357428360418466524768788874801
Employee Cost 10210094103124123136147175202
Other Costs 21242736491135485941761
Operating Profit 432975824027-362198-127135
Operating Profit Margin (%) 7.6%4.7%12.6%12.0%5.4%3.2%-31.2%15.4%-8.8%10.3%
Other Income 4443555766555814094128
Interest 8534414131815
Depreciation 22242323252628303340
Exceptional Items -30000-2490-145-190
Profit Before Tax 544310511276-195-335150-103208
Tax 1011373725-5047256347
Profit After Tax 4432687551-145-382125-165161
PAT Margin (%) 7.8%5.2%11.4%11.0%6.9%-17.4%-32.9%9.7%-11.5%12.3%
Adjusted EPS (₹)3.42.55.25.83.6-10.2-26.78.8-11.610.5
Dividend Payout Ratio (%)0%0%0%0%0%0%0%0%0%0%

Balance Sheet

(All Figures are in Crores.)
PARTICULARSMar'16Mar'17Mar'18Mar'19Mar'20Mar'21Mar'22Mar'23Mar'24Mar'25

Equity and Liabilities

Shareholders Fund 6666997678427125671863121442,305
Share Capital 11111114292931
Reserves 6656987668417115661712831152,275
Minority Interest0000000000
Debt5047335136231221422204
Long Term Debt1200000022160
Short Term Debt3847335136231221212044
Trade Payables4143866910890252178165220
Others Liabilities 927174855705851,2541,2591,567156
Total Liabilities 8498609601,0461,4261,2651,8141,8912,0952,685

Fixed Assets

Gross Block335353367389417442470513586675
Accumulated Depreciation104126147169191213237260287338
Net Fixed Assets 231227219220226229233253298338
CWIP 000011116957
Investments 2221212081149141139139366
Inventories1208812110612396179197162202
Trade Receivables116120121159178212304256234206
Cash Equivalents 230472126973356
Others Assets 3574014775377455769301,0201,1811,161
Total Assets 8498609601,0461,4261,2651,8141,8912,0952,685

Cash Flow

(All Figures are in Crores.)
PARTICULARSMar'16Mar'17Mar'18Mar'19Mar'20Mar'21Mar'22Mar'23Mar'24Mar'25
Cash Flow From Operating Activity 344713-22562289424891
PBT 544310511276-195-335150-103208
Adjustment -8-9-17-25-26-19-1256344-57
Changes in Working Capital -14194-49-23-28100-8243-11
Tax Paid -28-8-19-33-46-5-7-30-36-49
Cash Flow From Investing Activity 44-35-46-15-242-100-298-202-165-459
Capex -34-18-15-23-31-29-28-103-71-94
Net Investments 00010-190-00-275
Others 78-17-317-211-52-270-98-95-90
Cash Flow From Financing Activity -47-8-281530239590-21375
Net Proceeds from Shares 00003200000637
Net Proceeds from Borrowing 0-120000025-3-22
Interest Paid -8000-2-1-2-11-15-12
Dividend Paid 0000000000
Others -394-2815-1639776-3-228
Net Cash Flow 01-2338-4225-18628

Finance Ratio

PARTICULARSMar'16Mar'17Mar'18Mar'19Mar'20Mar'21Mar'22Mar'23Mar'24Mar'25
Ratios
ROE (%)6.834.759.249.36.54-22.73-101.4650.47-72.6613.15
ROCE (%)8.56.5713.8313.699.77-29.06-73.8342.75-20.4616.66
Asset Turnover Ratio0.660.740.660.680.60.620.750.690.720.55
PAT to CFO Conversion(x)0.071.381.040.04-0.43N/AN/A0.75N/A0.57
Working Capital Days
Receivable Days83687475838581796261
Inventory Days68606461574843534551
Payable Days503665676969811007288

Akums Drugs & Pharmaceuticals Ltd Stock News

Akums Drugs & Pharmaceuticals Ltd FAQs

The current trading price of Akums Drugs & Pharma on 05-Dec-2025 15:23 is ₹419.9.
Market capitalization or market cap is determined by multiplying the current market price of a company's shares with the total number of shares outstanding. As of 04-Dec-2025 the market cap of Akums Drugs & Pharma stood at ₹6,615.3.
The latest P/E ratio of Akums Drugs & Pharma as of 04-Dec-2025 is 48.26.
The latest P/B ratio of Akums Drugs & Pharma as of 04-Dec-2025 is 2.79.
The 52-week high of Akums Drugs & Pharma is ₹678.8 and the 52-week low is ₹407.4.
The TTM revenue is Trailing Twelve Months sales. The TTM revenue/sales of Akums Drugs & Pharma is ₹1,308 ( Cr.) .

About Akums Drugs & Pharmaceuticals Ltd

The company was incorporated as a public company, limited by shares, under the Companies Act, 1956, as amended, in the name of ‘Akums Drugs and Pharmaceuticals Limited’, pursuant to a certificate of incorporation dated April 19, 2004 issued by the Registrar of Companies, Delhi and Haryana in New Delhi (RoC). The company received a certificate of commencement of business issued by the RoC dated May 13, 2004. 

Established in 2004,  Akums Drugs and Pharmaceuticals is a pharmaceutical contract development and manufacturing organization (CDMO) offering a comprehensive range of pharmaceutical products and services in India and overseas. As one of the leading CDMOs in India, the company owns the intellectual property for the manufacturing processes of several of its formulations, and its core business is focused on providing end-to-end product development and manufacturing solutions to its clients. Some of its other services include formulation research and development (R&D), preparation and filing of regulatory dossiers in the Indian and global markets, and other testing services. In addition to its core CDMO business, it is also engaged in the manufacturing and sale of branded pharmaceutical formulations and active pharmaceutical ingredients (APIs).

Business area of the company 

As a CDMO, the company produces an extensive range of dosage forms including tablets, capsules, liquid orals, vials, ampoules, blow-filled seals, topical preparations, eye drops, dry powder injections, and gummies, among others. It also engages in the marketing of trade generic and products under its own brand through distributors and alternative channels across India.  

Key Awards and accreditations

  • 2018: Received India Pharma Leader Award by Government of India.
  • 2019: Received India Pharma Leader Award by Government of India.
  • 2021: Award for India Pharma Award for Excellence in Contract Research and Manufacturing by Informamarkets. 
  • 2022: Award for Excellence in R&D and Innovation by ET Ascent.
  • 2022: Awarded the International Healthcare award as Pharmaceutical Company of the Year in contract manufacturing by Times Cyber Media.
  • 2022: Awarded the Excellence in Operations – Manufacturing by CPHI Awards.
  • 2022: Awarded Asia’s Pharma Excellence Awards in Innovation in Nutraceutical, Cosmetic and Wellness Award by CMO Asia.
  • 2023: Awarded Dream Employer of the Year by Times Ascent.
  • 2023: Awarded the Excellence Award in Nutraceutical category by IHW Council.
  • 2023: Award for the best brand based in North India by Exchange4Media. 
  • 2023: Awarded the best Technology Adaption – Cash Management Services by HDFC Bank.
  • 2023: Awarded 2nd Runner up in Best Trademarks portfolio by CII Industrial Intellectual Property Awards. 
  • 2023: Awarded the Excellence in Formulations by India Pharma World Awards, The Economic Times. 
  • 2023: Awarded the Most Admired Quality Pharmaceutical Manufacturer of India 2023 by Observe Now. 
  • 2023: Awarded the Certificate of Appreciation for Excellence in Innovative Formulations – Nutraceutical and Wellness Award by Food Safety and Nutrition Summit and Awards 2023.

Major events and milestones

  • 2004: Incorporation of the company.
  • 2004: Established first plant for oral dosage commissioned at 19, 20, 21, sector 6A, Haridwar, Uttarakhand. 
  • 2007: Established dedicated manufacturing site for oral liquid dosage at 22, Sector 6A, Sidcul, Haridwar, Uttarakhand and sterile products at 2,3,4,5, Sector 6B, SIDCUL, Haridwar, Uttarakhand.
  • 2009: Incorporated Maxcure Nutravedics Limited to venture into nutraceuticals.
  • 2010: Dedicated a facility for hormones at 48, Sector 6A, SIDCUL, Haridwar, Uttarakhand.
  • 2010: Dedicated a facility for cosmetics and dermatology at 47, Sector 6A, SIDCUL, Haridwar, Uttarakhand.
  • 2010: Incorporated Akumentis Healthcare Limited to venture into branded formulations.
  • 2011: Innovated bi-layered sustained release tablets for the first time.
  • 2012: Acquired Pure and Cure Healthcare Private Limited to expand capacity and capabilities.
  • 2013: Innovated tablet-in-tablet sustained release tablets for the first time.
  • 2013: Acquired Malik Lifesciences Private Limited manufacturing sites to expand capacity and capabilities.
  • 2013: Expanded into the African market.
  • 2015: Expanded into the Asian market.
  • 2015: Established research and development laboratory in Mumbai, Maharashtra to venture into regulated market.
  • 2016: Maxcure Nutravedics Limited received US-NSF certification.
  • 2019: Investment by Ruby QC Investment Holdings Pte. Ltd. in the company to become a minority shareholder.
  • 2021: Acquired Parabolic Drugs to form Akums Lifesciences Limited and ventured into APIs.
  • 2021: Acquisition of a facility at Kotdwar, Uttarakhand by Akums Healthcare Limited.
  • 2022: Plant at 19, 20, 21, Sector 6A, SIDCUL, Haridwar, Uttarakhand and plant at 2, 3, 4,5, Sector 6B, SIDCUL, Haridwar, Uttarakhand accredited European Union-Good Manufacturing Practices, qualifying for exports to European markets.
  • 2022: Acquisition of a facility in Haridwar, Uttarakhand by Akums Healthcare Limited and a facility in Baddi, Himachal Pradesh by Pure and Cure Healthcare Private Limited.
  • 2023: Acquisition of another facility in Baddi, Himachal Pradesh by Pure and Cure Healthcare Private Limited.
  • 2023: Merger of Akums Lifesciences Limited with Pure and Cure Healthcare Private Limited.


To get DeciZen Rating of 3,500+ Stocks based on their Quality, Valuation and Price Trend Login Now

© 2025 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.

×